Board Change • 3h
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Chairman of the Board Gunnar Jardelöv was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. お知らせ • May 13
Vimab Group AB (publ), Annual General Meeting, Jun 09, 2026 Vimab Group AB (publ), Annual General Meeting, Jun 09, 2026, at 10:00 W. Europe Standard Time. Location: wigge & partners law kb`s premises, at birger jarlsgatan 25 in, stockholm Sweden お知らせ • Dec 03
Vimab Group AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 127.416758 million. Vimab Group AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 127.416758 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 26,545,158
Price\Range: SEK 4.8
Transaction Features: Rights Offering お知らせ • May 14
Vimab Group AB (publ), Annual General Meeting, Jun 10, 2025 Vimab Group AB (publ), Annual General Meeting, Jun 10, 2025, at 10:00 W. Europe Standard Time. Location: at wigge & partners advokat kb`s premises, at birger jarlsgatan 25, stockholm Sweden お知らせ • Dec 21
An undisclosed buyer signed a letter of intent to acquire Vimab Ab from Vimab Group AB (publ) (OM:VIMAB) for SEK 200 million. An undisclosed buyer signed a letter of intent to acquire Vimab Ab from Vimab Group AB (publ) (OM:VIMAB) for SEK 200 million on December 19, 2024. The divestment is intended to take place for a purchase price of approximately SEK 200 million on a cash and debt-free basis, which will be paid in cash when the shares are acquired. Net sales for Vimab AB in the financial year 2023 amounted to approximately SEK 200.1 million with an EBITDA result of approximately SEK 23.1 million, which corresponds to an EBITDA margin of approximately 11.5 percent. The divestiture is conditional on the Stakeholder's due diligence and the parties agreeing to enter into a share transfer agreement. Signing of the share transfer agreement and access is planned for the first quarter of 2025. Mangold Fondkommission AB acted as financial advisor for Vimab Group AB. Wigge & Partners Advokat Kb acted as legal advisor for Vimab Group AB. New Risk • Nov 05
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr5.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr5.8m free cash flow). Share price has been highly volatile over the past 3 months (35% average weekly change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (€22.2m market cap, or US$24.2m). Reported Earnings • Aug 25
Second quarter 2024 earnings released: kr0.20 loss per share (vs kr0.36 profit in 2Q 2023) Second quarter 2024 results: kr0.20 loss per share (down from kr0.36 profit in 2Q 2023). Revenue: kr96.7m (up 8.2% from 2Q 2023). Net loss: kr3.63m (down 150% from profit in 2Q 2023). New Risk • Jun 16
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr886k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr886k free cash flow). Minor Risks Shareholders have been diluted in the past year (9.9% increase in shares outstanding). Market cap is less than US$100m (€18.9m market cap, or US$20.2m). Reported Earnings • May 09
First quarter 2024 earnings released: kr0.80 loss per share (vs kr0.53 loss in 1Q 2023) First quarter 2024 results: kr0.80 loss per share (further deteriorated from kr0.53 loss in 1Q 2023). Revenue: kr68.5m (up 72% from 1Q 2023). Net loss: kr17.9m (loss widened 72% from 1Q 2023). お知らせ • May 08
Vimab Group AB (publ), Annual General Meeting, Jun 04, 2024 Vimab Group AB (publ), Annual General Meeting, Jun 04, 2024, at 10:00 W. Europe Standard Time. Location: wigge & partners advokat kb`s, premises at birger jarlsgatan 25, stockholm Sweden New Risk • Mar 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (€18.4m market cap, or US$20.1m). Reported Earnings • Mar 13
Full year 2023 earnings released: kr0.30 loss per share (vs kr3.44 loss in FY 2022) Full year 2023 results: kr0.30 loss per share (improved from kr3.44 loss in FY 2022). Revenue: kr347.8m (up 53% from FY 2022). Net loss: kr4.26m (loss narrowed 88% from FY 2022). Reported Earnings • Nov 15
Third quarter 2023 earnings released: EPS: kr0.20 (vs kr0.49 loss in 3Q 2022) Third quarter 2023 results: EPS: kr0.20 (up from kr0.49 loss in 3Q 2022). Revenue: kr99.7m (up 69% from 3Q 2022). Net income: kr4.86m (up kr12.0m from 3Q 2022). Profit margin: 4.9% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. New Risk • Oct 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Market cap is less than US$100m (€17.4m market cap, or US$18.4m).